These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. [Experience of twenty years in modern nomenclature of myeloproliferative and lymphoproliferative diseases]. Werner W Zentralbl Allg Pathol; 1982; 126(5-6):473-5. PubMed ID: 7158101 [No Abstract] [Full Text] [Related]
7. [Vasculitis and malignant diseases]. Gran JT Tidsskr Nor Laegeforen; 1997 Apr; 117(11):1627-9. PubMed ID: 9198948 [TBL] [Abstract][Full Text] [Related]
9. [New biomodulator treatment, treatment with interferon alpha in hematology and treatment using interleukin 2]. Castaigne S; Degos L Rev Prat; 1988 Jun; 38(17):1069-72. PubMed ID: 3043637 [No Abstract] [Full Text] [Related]
10. The myeloproliferative neoplasms: insights into molecular pathogenesis and changes in WHO classification and criteria for diagnosis. Anastasi J Hematol Oncol Clin North Am; 2009 Aug; 23(4):693-708. PubMed ID: 19577165 [TBL] [Abstract][Full Text] [Related]
11. Association of myeloproliferative and lymphoproliferative disorders. Gaillard JB; Carillo S; Henry L; Jourdan E; Lavabre-Bertrand T Clin Adv Hematol Oncol; 2012 Nov; 10(11):756-7. PubMed ID: 23271265 [No Abstract] [Full Text] [Related]
12. Cytogenetics. An evolving role in the diagnosis and treatment of cancer. Glassman AB Clin Lab Med; 1997 Mar; 17(1):21-37. PubMed ID: 9138897 [TBL] [Abstract][Full Text] [Related]
13. The effect of THF in lymphoproliferative and myeloproliferative diseases in children. Zaizov R; Vogel R; Wolach B; Cohen IJ; Varsano I; Shohat B; Handzel Z; Rotter V; Yakir Y; Trainin N Ann N Y Acad Sci; 1979; 332():172-83. PubMed ID: 294830 [No Abstract] [Full Text] [Related]
14. Classification of Philadelphia translocation-negative myeloproliferative neoplasms: its impact on data from clinical trials. Naresh KN J Clin Oncol; 2009 Nov; 27(31):e175-6; author reply e177-8. PubMed ID: 19704052 [No Abstract] [Full Text] [Related]
15. Hematologic problems of the aged. Vogel JM Mt Sinai J Med; 1980; 47(2):150-65. PubMed ID: 6993921 [No Abstract] [Full Text] [Related]
16. [Clinical picture of tuberculosis with concomitant hemoblastoses]. Iuldasheva NE; Karachunskiĭ MA; Pivnik AV Ter Arkh; 2004; 76(3):49-51. PubMed ID: 15108459 [TBL] [Abstract][Full Text] [Related]
17. [Problems of classification of lymphoproliferative disorders]. Bokarev IN; Khusainov VM Klin Med (Mosk); 1991 Apr; 69(4):3-7. PubMed ID: 1865645 [No Abstract] [Full Text] [Related]
18. Defining targets in myeloproliferative disorders: reflecting on what is important. Griesshammer M Hematol Oncol; 2009 Jun; 27 Suppl 1():2-4. PubMed ID: 19468984 [TBL] [Abstract][Full Text] [Related]
19. Essential thrombocythemia, polycythemia vera, and myelofibrosis: current management and the prospect of targeted therapy. Tefferi A Am J Hematol; 2008 Jun; 83(6):491-7. PubMed ID: 18429051 [TBL] [Abstract][Full Text] [Related]
20. [Register of hemoblastoses (the organization and management problems of dispensary care)]. Lebedev VN Sov Med; 1980; (11):102-5. PubMed ID: 6449748 [No Abstract] [Full Text] [Related] [Next] [New Search]